[1] |
XU Minyi, LIU Yaqi, LIU Yuxiu, XIONG Yin, GONG Haowen, ZHANG Manting, YU Xihui, ZHAO Yang.
BSD method for three treatments randomly allocated with equal proportion in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 283-289.
|
[2] |
WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun.
Clinical research progress of palbociclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
|
[3] |
DAI Jiahui, SUN Sijia, XIE Xuefeng.
Quality management and indicator system for clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
|
[4] |
MIAO Yadong, LI Xi, WANG Yan, GAO Po, ZHOU Min, YU Hao.
General considerations for clinical data management of antineoplastic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1055-1060.
|
[5] |
CHEN Jianfang, LOU Donghua.
Design of case report form for oncology clinical trials based on CDASH
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
|
[6] |
LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin.
Ethical analysis and countermeasures of artificial intelligence application in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
|
[7] |
ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li.
Clinical trials of inhalation in pediatric population in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
|
[8] |
ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang.
Research progress of PARP inhibitors in pancreatic cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
|
[9] |
SHE Zhihua, CHEN Zhou, LIANG Songyue.
Construction of informatization system of drug clinical trials ethical review based on cloud architecture
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
|
[10] |
OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin.
Ethical issues and countermeasures of early phase trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
|
[11] |
Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning.
Research progress in clinical trials of targeted drugs for gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
|
[12] |
ZHANG Qian, HU Wei, YU Bin, QIN Huiling, CHEN Mingzhuang, LU Chao.
Information construction of drug clinical trials based on literature analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 182-189.
|
[13] |
ZHANG Miao, LIU Qian, YAO Xueting, LIU Dongyang.
Exploration of early food effect study of innovative drugs based on physiologically-based pharmacokinetic absorption model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1426-1429.
|
[14] |
YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang.
Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
|
[15] |
JIANG Haihong, LI Xiao, LIU Yang.
Four dimensions of receiving overseas clinical trial data about drug and medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 835-840.
|